Search Results for "Thyroid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Thyroid. Results 21 to 30 of 84 total matches.
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
pancreatitis and acute gall bladder disease
Thyroid C-cell tumors reported in animals; contraindicated ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-3 doi:10.58347/tml.2024.1708c | Show Introduction Hide Introduction
Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
serum concentrations of
some systemic corticosteroids, and it can increase
thyroid-binding globulin ...
The FDA has approved a combination oral
contraceptive containing the estrogen estetrol and the
progestin drospirenone (Nextstellis – Mithra/Mayne).
Estetrol is the first new estrogen to become available
in the US in 50 years. Drospirenone is available alone
(Slynd) and in combinations with the estrogen ethinyl
estradiol for prevention of pregnancy.
Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 09, 2009 (Issue 1307)
in the alemtuzumab group
included autoimmune-related thyroid dysfunction in 49
patients (22.7%), immune ...
Alemtuzumab (Campath), a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS).
Two New GLP-1 Receptor Agonists for Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014 (Issue 1455)
,
and duration of these effects vary within the class.
GLP-1 receptor agonists have been shown to cause
thyroid ...
Two new injectable GLP-1 (glucagon-like peptide-1)
receptor agonists, dulaglutide (Trulicity [trū li si tee] –
Lilly) and albiglutide (Tanzeum [tan' zee um] – GSK),
have been approved by the FDA for once-weekly
treatment of type 2 diabetes. Other available GLP-1
receptor agonists include exenatide, which is approved
for injection twice daily (Byetta) or once weekly
(Bydureon), and liraglutide (Victoza), which is injected
once daily.
Liraglutide (Saxenda) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015 (Issue 1471)
. Thyroid C-cell tumors have been
reported in rodents given liraglutide, and the FDA has
required a boxed ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist liraglutide, previously approved by the
FDA for treatment of type 2 diabetes as Victoza, has
now also been approved at a higher dose as Saxenda
(Novo Nordisk) for chronic weight management
in adults with a BMI ≥30, or a BMI ≥27 with a
weight-related comorbidity such as hypertension,
dyslipidemia, or diabetes.
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017 (Issue 1529)
gastroparesis. GLP-1 receptor agonists have been
shown to cause thyroid C-cell tumors in animals ...
The FDA has approved Xultophy 100/3.6 (Novo
Nordisk), a fixed-ratio combination of insulin
degludec and the GLP-1 (glucagon-like peptide-1)
receptor agonist liraglutide, for once-daily treatment
of adults with type 2 diabetes inadequately controlled
on basal insulin (<50 units daily) or liraglutide (≤1.8
mg daily).
Extended-Release Exenatide (Bydureon) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Mar 19, 2012 (Issue 1386)
taking exenatide; whether they
were caused by the drug or the disease is not clear.
Thyroid C-cell ...
The FDA has approved a once-weekly extendedrelease
formulation of exenatide (Bydureon – Amylin),
an injectable glucagon-like peptide-1 (GLP-1) receptor
agonist, for treatment of type 2 diabetes.
Opdualag for Metastatic Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
, rash, arthralgia,
hypothyroidism or thyroiditis, diarrhea, and vitiligo were
reported in ≥10 ...
Opdualag (BMS), a fixed-dose combination of two
immune checkpoint inhibitors — nivolumab (Opdivo),
a programmed death receptor-1 (PD-1) inhibitor, and
relatlimab-rmbw, a lymphocyte-activation gene-3
(LAG-3) blocking antibody — has been approved by
the FDA for treatment of unresectable or metastatic
melanoma in patients ≥12 years old. Relatlimab, which
is only available in combination with nivolumab, is
the first LAG-3 blocking antibody to become available
in the US. Immune checkpoint inhibitors, including
the anti-CTLA-4 antibody ipilimumab (Yervoy) and
the PD-1 inhibitors...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e19-20 doi:10.58347/tml.2023.1668g | Show Introduction Hide Introduction
Tirzepatide (Zepbound) for Obstructive Sleep Apnea
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
a risk of thyroid
C-cell tumors (based on animal data; no corroborating
human data ...
The injectable glucose-dependent insulinotropic
polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)
receptor agonist tirzepatide (Zepbound) has been
approved by the FDA for treatment of moderate to
severe obstructive sleep apnea (OSA) in adults with
obesity. It is the first drug to be approved in the US for
this indication. Zepbound is also approved for chronic
weight management in adults with obesity and in those
who are overweight and have at least one weightrelated
comorbidity. Tirzepatide is also available as
Mounjaro for treatment of type 2 diabetes.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):29-31 doi:10.58347/tml.2025.1722c | Show Introduction Hide Introduction
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019 (Issue 1583)
agonists (not lixisenatide),
the label of semaglutide includes a boxed
warning about a risk of thyroid C ...
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation (Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.